Seth A. Wander, Ph.D.
Affiliations: | 2011 | Cancer Biology (Medicine) | University of Miami, Coral Gables, FL |
Area:
Molecular Biology, OncologyGoogle:
"Seth Wander"Parents
Sign in to add mentor| Joyce M. Slingerland | grad student | 2011 | University of Miami | |
| (p27 and metastatic progression: Molecular mechanisms underlying bone metastasis.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Wander SA, Bardia A. (2024) Cracking the Genomic Code of CDK4/6 Inhibitor Resistance. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
| Gerratana L, Davis AA, Velimirovic M, et al. (2023) Interplay between ESR1/PIK3CA codon variants, oncogenic pathway alterations and clinical phenotype in patients with metastatic breast cancer (MBC): comprehensive circulating tumor DNA (ctDNA) analysis. Breast Cancer Research : Bcr. 25: 112 |
| Brett JO, Dubash TD, Johnson GN, et al. (2023) A Gene Panel Associated With Abemaciclib Utility in -Mutated Breast Cancer After Prior Cyclin-Dependent Kinase 4/6-Inhibitor Progression. Jco Precision Oncology. 7: e2200532 |
| Gerratana L, Davis AA, Velimirovic M, et al. (2023) Cyclin-Dependent Kinase 4/6 Inhibitors Beyond Progression in Metastatic Breast Cancer: A Retrospective Real-World Biomarker Analysis. Jco Precision Oncology. 7: e2200531 |
| Lloyd MR, Wander SA, Hamilton E, et al. (2022) Next-generation selective estrogen receptor degraders and other novel endocrine therapies for management of metastatic hormone receptor-positive breast cancer: current and emerging role. Therapeutic Advances in Medical Oncology. 14: 17588359221113694 |
| Wander SA, O'Brien N, Litchfield LM, et al. (2022) Targeting CDK4 and 6 in Cancer Therapy: Emerging Preclinical Insights Related to Abemaciclib. The Oncologist |
| Lloyd MR, Spring LM, Bardia A, et al. (2021) Mechanisms of Resistance to CDK4/6 Blockade in Advanced Hormone Receptor-positive, HER2-negative Breast Cancer and Emerging Therapeutic Opportunities. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
| Jiang X, Lu X, Gentles AJ, et al. (2021) HGAL inhibits lymphoma dissemination by interacting with multiple Cytoskeletal proteins. Blood Advances |
| Wander SA, Han HS, Zangardi ML, et al. (2021) Clinical Outcomes With Abemaciclib After Prior CDK4/6 Inhibitor Progression in Breast Cancer: A Multicenter Experience. Journal of the National Comprehensive Cancer Network : Jnccn. 1-8 |
| Mao P, Cohen O, Kowalski KJ, et al. (2020) Acquired FGFR and FGF alterations confer resistance to estrogen receptor (ER) targeted therapy in ER+ metastatic breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |